Alzheimer’s Disease (AD) is the leading age-associated neurodegenerative disorder, affecting more than 50 million people globally. No therapies exist to prevent, delay or treat AD. Current therapies target cognitive function and provide modest short-term benefit while not affecting disease progression.
Parkinson’s disease is a brain disorder, causing nerve cells in an area of that brain that controls movement to become impaired and/or die. When impaired, these nerve cells or neurons produce less dopamine, which causes movement issues.
Multiple Sclerosis is a potentially disabling disease of the brain and the central nervous system, where the immune system attacks the protective sheath (myelin), resulting in communications challenges between the brain and the body.
Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressing, fatal neurodegenerative disorder. Deterioration of motor neurons results in the loss of voluntary movement control, and eventually breathing. The median life expectancy is three to five years after diagnosis.
– Roberta Diaz Brinton, PhD., Director
– Kathleen Rodgers, PhD., Associate Director of Translational Neuroscience